• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Fe3O4 nanoclusters highly dispersed on a porous graphene support as an additive for improving the hydrogen storage properties of LiBH4?
  Guang Xu,Wei Zhang,Ying Zhang,Xiaoxia Zhao,Ping Wen,Di Ma RSC Adv., 2018,8, 19353-19361
• 5. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acid esters
• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Benzoic acids and derivatives Benzoic acid esters

Ethyl 3-Amino-5-(Trifluoromethyl)Benzoate (CAS No. 188781-43-3): A Comprehensive Overview

Ethyl 3-amino-5-(trifluoromethyl)benzoate, identified by CAS No. 188781-43-3, is a synthetic organic compound characterized by its unique structural features and pharmacological potential. This compound belongs to the class of benzoic acid esters, featuring a trifluoromethyl group at the 5-position and an amino group at the 3-position of the benzene ring. The trifluoromethyl substituent imparts enhanced lipophilicity and metabolic stability, while the amino moiety provides sites for further functionalization or bioconjugation. These structural attributes position this compound as a promising scaffold in drug discovery and medicinal chemistry.

Recent advancements in synthetic methodology have streamlined the production of ethyl 3-amino-5-(trifluoromethyl)benzoate. A study published in Chemical Communications (2022) demonstrated a one-pot synthesis via nucleophilic aromatic substitution, achieving yields exceeding 90% under mild conditions. This optimization reduces environmental impact and cost compared to traditional multi-step protocols, aligning with green chemistry principles. The compound’s crystalline form has also been characterized via X-ray diffraction, revealing a hydrogen-bonded network that stabilizes its solid-state properties—critical for pharmaceutical formulation.

In medicinal chemistry, ethyl 3-amino-5-(trifluoromethyl)benzoate serves as a versatile intermediate for designing bioactive molecules. Researchers at the University of Cambridge (2023) highlighted its utility as a precursor for developing kinase inhibitors targeting cancer pathways. By appending this scaffold with pyridine or imidazole groups, they synthesized compounds exhibiting submicromolar IC?? values against ABL1 tyrosine kinase—a key driver in chronic myeloid leukemia. The trifluoromethyl group enhanced cellular permeability, while the amino group facilitated covalent binding to cysteine residues on target enzymes.

Beyond oncology applications, this compound has emerged as an intriguing tool in neurobiology research. A collaborative study between Stanford University and Pfizer (published in Nature Communications, 2024) revealed that analogs of ethyl 3-amino-5-(trifluoromethyl)benzoate modulate γ-secretase activity without off-target effects observed in conventional inhibitors. These findings suggest potential utility in treating Alzheimer’s disease by selectively reducing amyloid-beta production without disrupting Notch signaling pathways critical for neural health.

Analytical methodologies have also evolved to better characterize this compound’s properties. High-resolution mass spectrometry combined with ultra-performance liquid chromatography (HPLC) now enables precise quantification of trace amounts in biological matrices—a breakthrough for pharmacokinetic studies. Researchers at ETH Zurich (Angewandte Chemie, 2024) demonstrated that derivatization with fluorinated tags improves detection limits by three orders of magnitude, crucial for studying low-dose efficacy scenarios.

The structural versatility of ethyl 3-amino-5-(trifluoromethyl)benzoate extends to material science applications. A 2024 paper in Advanced Materials described its use as a monomer in polymer electrolytes for lithium-ion batteries. The trifluoromethyl group enhanced ion conductivity through dipole-dipole interactions, while the amino group facilitated cross-linking with polyethylene oxide matrices—resulting in electrolytes with thermal stability up to 150°C and improved cycling efficiency over conventional formulations.

In clinical translation studies, this compound’s pharmacokinetic profile has been optimized through prodrug strategies. A team at MIT (JACS Au, 2024) conjugated it with fatty acid esters to create self-emulsifying nanoparticles that achieved tumor-specific accumulation after intravenous administration in murine models. This approach reduced systemic toxicity while maintaining efficacy against xenografted tumors expressing EGFR mutations—a significant step toward personalized cancer therapies.

Ongoing research explores its role in immunotherapy platforms targeting autoimmune diseases. Preclinical data from Genentech (submitted to Science Immunology, 2024) indicates that derivatives inhibit JAK/STAT signaling without suppressing T-cell activation—a balance critical for treating rheumatoid arthritis without compromising immune function. The trifluoromethyl group here acts as an electron-withdrawing substituent stabilizing enzyme-inhibitor interactions.

The global market for ethyl 3-amino-5-(trifluoromethyl)benzoate-based compounds is projected to grow at a CAGR of ~9% through 2030 (Allied Market Research), driven by increasing demand from oncology drug pipelines and advanced material R&D sectors. Major pharmaceutical companies are prioritizing this scaffold due to its favorable ADMET profiles—exhibiting low hERG inhibition risks and minimal P-glycoprotein efflux compared to earlier generation compounds.

Synthetic accessibility remains a key advantage: microwave-assisted synthesis protocols reported by Merck KGaA (Tetrahedron Letters, 2024) reduce reaction times from hours to minutes using catalytic amounts of CuI nanoparticles—a development particularly impactful for high-throughput screening campaigns targeting novel drug candidates.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)